<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755183</url>
  </required_header>
  <id_info>
    <org_study_id>08-004-16</org_study_id>
    <nct_id>NCT00755183</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction</brief_title>
  <official_title>A Single-Center, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Testosterone 0.03% Ophthalmic Solution Compared to Vehicle for the Treatment of Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Jerome Crampton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ORA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of testosterone 0.03%
      ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meibomian gland secretion plays a crucial role in the health of the ocular surface and
      function of the tear film. The lipid secreted by the meibomian glands has many crucial roles:
      1) to retard evaporation from the preocular surface; 2) lower the surface tension of tears;
      3) prevent spill-over of tears from the lid margin; 4) prevent the contamination of the tear
      film by sebaceous lipids; 5) prevent damage to the skin of the lid margin. In dry eye
      syndrome, blepharitis, meibomian gland dysfunction, and meibomitis the glands are the central
      pathophysiology of disease and thus a potential target for therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>meibomian glad secretion</measure>
    <time_frame>128 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comfort</measure>
    <time_frame>128 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>testosterone ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>testosterone ophthalmic solution 0.03%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle of testosterone ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone ophthalmic solution</intervention_name>
    <description>testosterone ophthalmic solution for 128 days</description>
    <arm_group_label>testosterone ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle of testosterone ophthalmic solution</intervention_name>
    <description>vehicle of testosterone ophthalmic solution for 128 days</description>
    <arm_group_label>vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (subjects must):

          -  Be ≥ 60 years of age

          -  Have a corrected visual acuity of LogMAR +0.5 (ETDRS)

          -  Have a documented history of Meibomian Gland Dysfunction

          -  Have a TFBUT ≤ 5 seconds

          -  Have an ocular discomfort score ≥ 1

          -  Have an IOP ≤ 25 mmHg at Visit 1 in both eyes

          -  Report use of and/or desire to use an artificial tears

        Exclusion Criteria (subjects may not):

          -  Have contraindications to the use of the study medications

          -  Have a known allergy or sensitivity to the study medications

          -  Have any ocular infections, or active ocular inflammation

          -  Have used ocular medications within 24 hours prior to Visit 1

          -  Be a current contact lens wearer

          -  Require the use of any other ophthalmic medication, other than tear substitutes and
             study medication provided, for the duration of the trial

          -  Have used systemic or topical antihistamines or steroids 48 hours prior to Visit 1 or
             require the use of systemic or topical antihistamines or steroids during the course of
             the study

          -  Have a history of prostate cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Jerome Crampton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ORA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Research Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <disposition_first_submitted>March 15, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 19, 2012</disposition_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>ORA, Inc.</investigator_affiliation>
    <investigator_full_name>H. Jerome Crampton</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Meibomian Gland Dysfunction</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

